PatientLive Oncology: the online real-time patient insights solution launches 18 new conditions in the oncology therapeutic area worldwide.

Today Carenity, part of the technology-driven data science group EvidentIQ, announced that its PatientLive solution is broadening its offer by entering the oncology therapeutic area. The PatientLive Oncology platform grants access to real-time insights and reliable answers from cancer patients and caregivers with quick surveys.

PatientLive was created by Carenity in 2016 with the purpose of offering pharma companies a unique, compliant, and fast way to get access to real-time patient insights. The Carenity team believes that guesswork is no longer enough, but knows that time is also valuable. This is why Patient Live allows users to get quick answers from patients to make better decisions.

Carenity’s mission is to help improve medical knowledge and care for chronic patients, including patients with cancer, which is the driving force behind the opening of 18 new PatientLive conditions. These conditions, both in hematology and solid tumors, are: bladder cancer, breast cancer, colorectal cancer, esophageal cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, liver cancer, lung cancer, mouth cancer, multiple myeloma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, skin cancer, throat cancer, thyroid cancer, and tongue cancer.

Until today, PatientLive offered access to a worldwide online panel of 500,000 patients and caregivers in the following conditions: ankylosing spondylitis, arterial hypertension, asthma, bipolar disorder, COPD, Crohn’s disease, depression, Diabetes (Types 1 and 2), epilepsy, fibromyalgia, lupus, multiple sclerosis, NASH, obesity, osteoarthritis, psoriasis, and rheumatoid arthritis.

Michael Chekroun, Chief Strategy and Transformation Officer at EvidentIQ group and Founder of Carenity, tell us about this new offering:

“PatientLive has always offered quick responses and has been valued for its simplicity and autonomy of use. We want now to make this available for pharma companies focused on oncology and keep this virtuous circle of Data for Good going.”

More about PatientLive

PatientLive is a SaaS platform that allows users to acquire real-time insights through a five-question survey. Five types of questions are available: single choice, multiple choice, 0 to 5 scale, text field, numeric field, and image/video test. Users can access results in real-time, from day 1. Surveys on PatientLive initiate patients’ data generation on topics including: disease/treatment burden, unmet needs, quality of life, services and communication message testing, and information and service needs. These early insights are invaluable for PatientLive users as they enable better patient-centric solutions and materials, and may guide the development of further non-observational studies and Real World Evidence projects.

 

Über die EvidentIQ Group GmbH

EvidentIQ is a next generation technology-amplified data science group championing new standards in value creation and innovation driven relevance for customers. The EvidentIQ offering brings a pioneering end to end eClinical solution that meets increasing customer demand across clinical operations and clinical data management needs with a suite of applications within a single integrated cloud platform. By combining its platform with a broad data science service portfolio such as patient recruitment, patient engagement media and a host of RWE late phase solutions EvidentIQ significantly helps customers optimize HTA submissions, pricing and reimbursement needs.

EvidentIQ supports 15 of the top 20 pharma companies through novel RWE solutions and 150+ SMB customers in over 20 countries, including US, Germany, France, UK, Italy, Japan and China.

Firmenkontakt und Herausgeber der Meldung:

EvidentIQ Group GmbH
Rathausmarkt 5
20095 Hamburg
Telefon: +49 (89) 4522775000
Telefax: +49 (89) 4522775900
https://evidentiq.com

Ansprechpartner:
Thomas Verjus
Telefon: +33(0)6 45 71 33 37
E-Mail: thomas@carenity.com
Für die oben stehende Story ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel